Summary Slide.png (61.12 kB)

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Download (61.12 kB)
figure
posted on 08.08.2019 by Marilyn K. Glassberg, Steven D. Nathan, Chin-Yu Lin, Elizabeth A. Morgenthien, John Stauffer, Willis Chou, Paul W. Noble

Provide enhanced digital features for this article

If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact adisrapidplus@springer.com.

The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.

Other enhanced features include, but are not limited to:
• Slide decks
• Videos and animations
• Audio abstracts
• Audio slides

Funding

F. Hoffmann-La Roche Ltd. and Genentech, Inc.

History

Exports